Designing & Delivering Early Access for Gene Therapies: Lessons from Lenadogene Nolparvovec in Leber Hereditary Optic Neuropathy
Time: 10:30 am
day: Day 2
Details:
• Meeting urgent unmet need in Leber Hereditary Optic Neuropathy through early access
• Exploring unique considerations for gene therapy in rare disease populations
• Overcoming operational, regulatory, and logistical hurdles throughout the EAP journey
• Actionable insights and takeaways for future gene therapy early access programmes
